Ero Copper (ERO) +17%

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. 

Its flagship asset includes Caraíba operations that comprise the production and sale of copper concentrates located in northeastern Bahia State, Brazil, as well as gold and silver produced and sold as by-products. 

• Sector: Basic Materials
• Industry: Copper
• Full Time Employees: 3,690
• Incorporated in 2016 
• Headquartered in Vancouver, Canada
• https://erocopper.com

Natera (NTRA) : 10-year performance

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis,  Anora products of conception (POC) and non-invasive paternity testing (PAT). 

Founded by Matthew Rabinowitz and Jonathan Sheena in 2003

Headquartered in Austin, TX

Ticker: NTRA

 

 

 

  

Natera is a global leader in cell-free DNA testing. The mission of the Company is to change the management of disease worldwide. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. The Company offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including bio pharmaceutical companies and genetic laboratories through its cloud-based software platform. 

Cidara Therapeutics (CDTX) to be acquired by Merck (MRK) for $9.2B or $221.50 per share

Cidara Therapeutics to be acquired by Merck (MRK) for $221.50 per share in cash

• Merck (MRK) agreed to acquire Cidara Therapeutics (CDTX) for $221.50/share in cash, valuing the transaction at ~$9.2B, as part of its strategy to broaden its infectious disease pipeline.
• Deal centers on CD388, a long-acting, strain-agnostic antiviral in Phase 3 (ANCHOR) for preventing influenza in high-risk individuals; the candidate has Breakthrough Therapy and Fast Track designations and showed strong efficacy in the Phase 2b NAVIGATE trial.
• CD388 combines a neuraminidase inhibitor with a proprietary Fc-antibody fragment, aiming to provide a durable prevention option beyond vaccines and traditional antivirals.
  
• Boards of both companies have approved the transaction; closing is expected in Q1 2026, pending a successful tender offer, HSR clearance, and customary conditions.

  

 

The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 38
• Incorporated in 2012 
• Based in San Diego, California
• https://www.cidara.com

Leifras (LFS) began trading on the Nasdaq on Thur 9 Oct 25

Headquartered in Tokyo, Leifras is a sports and social business company dedicated to youth sports and community engagement. 

 

The Company primarily provides services related to the organization and operations of sports schools and sports events for children. As of December 31, 2024, Leifras was recognized as one of Japan's largest operators of children's sports schools in terms of both membership and facilities by Tokyo Shoko Research. 

• Headquarters: Japan
• Founded: August 27, 2001
• https://leifras.co.jp/

Scholar Rock (SRRK) reported Q3 earnings on Fri 14 Nov 25 (b/o)

Scholar Rock Holding Corp. is a biopharmaceutical company.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 128
• Founded by Timothy A. Springer and Leonard I. Zon in  2012
• Headquartered in Cambridge, Massachusetts.
• https://www.scholarrock.com

 

The company announced the results of its earnings performance in the third quarter of the year, where it widened its net loss by 58 percent to $102 million from $64.5 million in the same period last year, pulled down by a 60 percent higher operating loss of $103.5 million versus $64.78 million year-on-year.

Scholar Rock investor sentiment was boosted by the progress of its drug candidate for spinal muscular atrophy (SMA).

In an updated report, Scholar Rock Holding Corp. (NASDAQ:SRRK) said that it completed “constructive and collaborative” in-person meeting with the Food and Drug Administration last Wednesday, November 12, for its biologics license application of apitegromab.

Scholar Rock Holding Corp.  said BLA resubmission and US launch is anticipated by next year.

Additionally, it said that it targets to secure the approval of the European Medicines Agency (EMA) to sell apitegromab to Europe by mid 2026.

Figure Technology Solutions (FIGR) reported Q3 earnings on Thur 13 Nov 25 (a/h)

• Strong Q3 2025 earnings beat, with net income tripling year-over-year, fueled the 21.62% intraday gain

 

Figure Technology Solutions released its Q3 2025 results after market close on November 13, revealing earnings per share of $0.34, surpassing analyst estimates, alongside revenue of $156.37 million driven by robust growth in its tokenized consumer loan marketplace. Net income soared nearly 227% to approximately $90 million, while adjusted EBITDA climbed 75% to $86 million, highlighting the success of its blockchain-based lending platform amid expanding partnerships and marketplace volumes. The earnings call on November 14 at market open amplified positive forward guidance on SMB lending and tokenization initiatives, prompting investor enthusiasm and high trading volume that propelled the sharp price advance during regular hours.

Relay Therapeutics (RLAY) reported Q3 earnings on Thur 6 Nov 25 (a/h)

Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease.

• It reported third quarter 2025 financial results today, including a net loss of $74.1 million, and announced the appointment of Lonnel Coats and Habib Dable to its Board of Directors.

** charts before earnings **

 

** after earnings **

Intellia Therapeutics (NTLA) reported Q3 earnings on Thur 6 Nov 25 (a/h)

Intellia Therapeutics announced third quarter 2025 financial results and provided updates on its MAGNITUDE and MAGNITUDE-2 Phase 3 trials, including the recent patient death and ongoing FDA clinical hold, with a conference call scheduled for today at 6:00 p.m. ET.

 

** before earnings **

** after earnings **